70709-191-12 : NDC 2026 Code

70709-191-12 : Nilotinib ( Cavhanza )

Additionally :

You can get information about “70709-191-12” NDC code in 70709-191-12 in HTML format

HTML | 70709-191-12 in TXT (Plain Text) format

TXT | 70709-191-12 in PDF (Portable Document Format)

PDF | 70709-191-12 in XML format

XML formats.

NDC Code : 70709-191-12 – JSON Data Format

                
{
  "NDC": {
    "NDCCode": "70709-191-12",
    "PackageDescription": "112 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (70709-191-12) ",
    "NDC11Code": "70709-0191-12",
    "ProductNDC": "70709-191",
    "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
    "ProprietaryName": "Cavhanza",
    "ProprietaryNameSuffix": null,
    "NonProprietaryName": "Nilotinib",
    "DosageFormName": "TABLET, ORALLY DISINTEGRATING",
    "RouteName": "ORAL",
    "StartMarketingDate": "20260630",
    "EndMarketingDate": null,
    "MarketingCategoryName": "NDA",
    "ApplicationNumber": "NDA217379",
    "LabelerName": "Cycle Pharmaceuticals Ltd",
    "SubstanceName": "NILOTINIB",
    "StrengthNumber": "60",
    "StrengthUnit": "mg/1",
    "Pharm_Classes": "Bcr-Abl Tyrosine Kinase Inhibitors [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C8 Inducers [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Kinase Inhibitor [EPC], P-Glycoprotein Inhibitors [MoA], UGT1A1 Inhibitors [MoA]",
    "DEASchedule": null,
    "Status": "Active",
    "LastUpdate": "2026-08-12",
    "PackageNdcExcludeFlag": "N",
    "ProductNdcExcludeFlag": "N",
    "ListingRecordCertifiedThrough": "20271231",
    "StartMarketingDatePackage": "20260630",
    "EndMarketingDatePackage": null,
    "SamplePackage": "N"
  }
}